MY 1250 | CAS#63768-47-8 | antihistamine

MedKoo Cat#: 584764 | Name: MY 1250

Description:

WARNING: This product is for research use only, not for human or veterinary use.

MY 1250, also known as BAY-w 8199, is an active metabolite of Repirinast that inhibits histamine release from rat mast cells.

Chemical Structure

MY 1250

CAS#63768-47-8

Theoretical Analysis

MedKoo Cat#: 584764

Name: MY 1250

CAS#: 63768-47-8

Chemical Formula: C15H11NO5

Exact Mass: 285.0637

Molecular Weight: 285.26

Elemental Analysis: C, 63.16; H, 3.89; N, 4.91; O, 28.04

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

MY 1250; MY-1250; MY1250; BAY-w 8199; BAY-w8199; BAY-w-8199; BAYw 8199; BAYw8199; BAYw-8199;

IUPAC/Chemical Name

4H-Pyrano(3,2-c)quinoline-2-carboxylic acid, 5,6-dihydro-7,8-dimethyl-4,5-dioxo-

InChi Key

KKCFYNQIBLXNSC-UHFFFAOYSA-N

InChi Code

InChI=1S/C15H11NO5/c1-6-3-4-8-12(7(6)2)16-14(18)11-9(17)5-10(15(19)20)21-13(8)11/h3-5H,1-2H3,(H,16,18)(H,19,20)

SMILES Code

O=C(C(O1)=CC(C2=C1C3=C(NC2=O)C(C)=C(C)C=C3)=O)O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 285.26 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Takei M, Endo K, Takahashi K. Inhibition of histamine release from rat peritoneal mast cells by MY-1250, an active metabolite of Repirinast (MY-5116). Int Arch Allergy Appl Immunol. 1990;93(2-3):237-41. PubMed PMID: 1712003. 2: Yamada N, Arai Y, Funayama K, Kadowaki S, Takahashi K, Umezu K. Effect of a major metabolite of the antiallergic drug repirinast on phosphodiesterase and adenylate cyclase activities. Arzneimittelforschung. 1995 Jan;45(1):33-5. PubMed PMID: 7534459. 3: Horii D, Hara Y, Hanazuka M, Nishi H. [Cardiovascular effects of MY-5116 and MY-1250]. Nihon Yakurigaku Zasshi. 1986 Apr;87(4):417-26. Japanese. PubMed PMID: 3087848. 4: Takahashi K, Yamada N, Endoh K, Yasumura K. Effects of MY-1250, a main active metabolite of MY-5116, a new anti-allergic agent, on the release of mediators from guinea pig lung fragments. Arerugi. 1986 Sep;35(9):982-7. PubMed PMID: 2432858. 5: Takei M, Endo K, Takahashi K. Mechanism of action of MY-1250, an active metabolite of Repirinast, in inhibiting histamine release from rat mast cells. Br J Pharmacol. 1992 Mar;105(3):587-90. PubMed PMID: 1378339; PubMed Central PMCID: PMC1908474. 6: Yamada N, Kadowaki S, Takahashi K, Umezu K. MY-1250, a major metabolite of the anti-allergic drug repirinast, induces phosphorylation of a 78-kDa protein in rat mast cells. Biochem Pharmacol. 1992 Sep 25;44(6):1211-3. PubMed PMID: 1358073. 7: Kohno SW, Ohata K. [Antiallergic effect of MY-5116 and its major metabolite, MY-1250]. Arerugi. 1986 Nov;35(11):1105-12. Japanese. PubMed PMID: 2435266. 8: Kamei C, Mio M, Izushi K, Yoshii N, Fujisawa K, Tasaka K. Inhibitory effect of MY-1250 on histamine release from rat peritoneal mast cells and guinea pig lung fragments: the elucidation of the mechanism. Immunopharmacol Immunotoxicol. 1991;13(3):341-56. PubMed PMID: 1719061. 9: Yamada N, Takahashi K, Endoh K, Arai Y. [Inhibitory effect on the release of mediators from rat peritoneal exudate cells and the antagonistic effect against mediators of MY-5116 and other anti-allergic agents]. Nihon Yakurigaku Zasshi. 1986 Sep;88(3):229-37. Japanese. PubMed PMID: 2431983. 10: Takahashi K, Shono T. [Effects of MY-1250, a main active metabolite of MY-5116, a new anti-allergic drug, on histamine release from monkey lung fragments]. Arerugi. 1986 Sep;35(9):975-81. Japanese. PubMed PMID: 2432857. 11: Ma H, Kovanen PT. Inhibition of mast cell-dependent conversion of cultured macrophages into foam cells with antiallergic drugs. Arterioscler Thromb Vasc Biol. 2000 Dec;20(12):E134-42. PubMed PMID: 11116078. 12: Takahashi K, Shono T, Arai Y. [Effects of MY-1250, a main active metabolite of MY-5116, a new anti-allergic drug, on histamine release from rat peritoneal exudate cells and the degranulation of mesenteric mast cells]. Arerugi. 1986 Oct;35(10):1028-36. Japanese. PubMed PMID: 2434065. 13: Beermann D, Schaefer HG, Wargenau M, Heibel B, Sturm Y, Kuhlmann J. Pharmacokinetics of the active metabolite of the prodrug repirinast in healthy Caucasian volunteers after a single oral dose. Eur J Clin Pharmacol. 1992;42(3):307-12. PubMed PMID: 1315685.

View History

Mycosidine

MedKoo CAT#: 208417

CAS#: 181465-11-2